Trusted Supply of Critical & Orphan Medicines, Worldwide!

Drug: Tucatinib
Brand: Tucatinib 150mg
Manufacturer /
TM Owner
Seagen / Pfizer
Origin: USA

Tucatinib 150mg Tablet

Tucatinib contains Tucatinib, a targeted kinase inhibitor. It blocks specific enzymes that drive cancer cell growth and survival, offering a precision alternative to conventional chemotherapy. It is used in the treatment of breast cancer. It is supplied as a tablet (150mg). Available on prescription, it forms part of modern, guideline-driven care.
Strength: 150mg
Pack Size: 84s
Storage: 20°C to 25°C
Form: Tablet

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More

Secure Handling

24/7 Worldwide Support

Global Access

Worldwide Access to Health

Cold-Chain Expert

Excellence in Cold-Chain

Trusted Supply

Certified Medical Supply

Indications & Clinical Uses

  • Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
  • Tucatinib is a selective tyrosine kinase inhibitor targeting HER2, used as part of triplet therapy after prior trastuzumab (Herceptin) and pertuzumab (Perjeta) or equivalent regimens.
  • This is a hospital- or clinic-administered protocol requiring comprehensive monitoring.
  • Patients must have adequate hepatic and renal function before starting.
  • Tucatinib is not for use as a single agent.

Side Effects

  • Diarrhea is the most frequent serious adverse effect, occurring in 82% of patients with 13% experiencing severe (Grade 3+) diarrhea.
  • Severe diarrhea can cause dehydration, hypotension, acute kidney injury, and death if not managed promptly.
  • Nausea and vomiting occur commonly.
  • Stomatitis (mouth sores) and oral ulceration affect many patients, requiring good oral hygiene.
  • Liver enzyme elevation (ALT/AST) occurs frequently and requires blood monitoring.
  • Rash, joint pain, and weight loss are reported.
  • Nosebleeds (epistaxis) may occur.
  • Serious adverse reactions occur in 29% of patients.
  • Seek immediate attention for severe diarrhea, vomiting lasting more than a few hours, or signs of dehydration.

Precautions & Warnings

  • Diarrhea is a dose-limiting toxicity; patients must be counseled on management and when to seek urgent care.
  • Monitor liver function tests (ALT, AST, total bilirubin) every three weeks during treatment and more frequently if abnormalities develop.
  • Renal function monitoring essential; serum creatinine may increase without indicating true kidney dysfunction.
  • May cause fetal harm; women of childbearing age must use effective contraception during and for one week after treatment.
  • Men must also use contraception due to potential testicular toxicity.
  • Strong CYP3A inhibitors require tucatinib dose reduction.
  • Adequate hepatic function required for use.
  • Interstitial lung disease and hepatotoxicity risk; monitor for respiratory symptoms and fatigue.

Avoid Interactions

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, protease inhibitors, clarithromycin) increase tucatinib levels and require dose reduction to 100 mg twice daily; coordinate with your doctor.
  • Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) decrease tucatinib effectiveness and may require dose increase.
  • Moderate CYP3A4 inhibitors and inducers also warrant monitoring and possible adjustment.
  • Capecitabine and trastuzumab are required companion drugs; discontinuing either stops tucatinib benefit.
  • Grapefruit and grapefruit juice must be avoided as they inhibit CYP3A4.
  • Tell your healthcare provider about all medications, supplements, and herbal products before starting tucatinib therapy.

References

Frequently Asked Questions

Tucatinib (150 mg tablets) treats HER2-positive metastatic breast cancer in adults who have received at least two prior anti-HER2 treatments. It is taken with trastuzumab and capecitabine as triplet therapy. Tucatinib blocks HER2 signaling to slow cancer growth and is used only after progression on other HER2-targeted drugs.

Simple Working Process

We have simplified the online drug ordering process into 4 easy steps to ensure
a safe, secure, and hassle-free experience for our customers.


Order Online

Place your order online and upload prescription in minutes with ease.



Order Confirmation

We verify your prescription and confirm your order quickly and securely.



Prescription Review

Reviewed by licensed pharmacists. Carefully processed and validated.

R

Receive Medicines

Approved order delivered fast, easy, and right to your doorstep or nearby Airport.



Global Standards. Trusted Care.

Trusted & Reliable – Your Partner in Global Distribution.

We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.